Perifosine + Sunitinib Malate for Patients With Advanced Cancers

Perifosine + Sunitinib Malate for Patients With Advanced Cancers

Renal Cancer; GIST

Completed

1

Start Date 10/01/2006

Age of Trial (yrs) 17.6

Gleevec-resistant

AKT inhibitor

Block KIT Signal Path

Specifically GIST plus other cancers

Perifosine 125

AOI Pharma, Inc.

Online Collaborative Oncology Group

ocogtrials@ocog.net

415-946-2410

Oral

Note: When contacting please refer to this study by ClinicalTrials.gov identifier NCT00399152.
Note: OCOG is the single point of contact for all Perifosine trial sites.
This study has been terminated. (AOI Pharma is reassessing the development strategy for perifosine).

2/17/09 AOI Pharma is reassessing the development strategy for perifosine